Key Takeaways:
Embecta Corp. faces at least three securities class action lawsuits after its shares plunged 58% on May 5 following weak second-quarter results and a guidance cut.
"Embecta misled investors about the strength of its pen needle segment and its fiscal 2026 outlook," the complaint filed by Gainey McKenna & Egleston in the US District Court for the District of New Jersey said.
The lawsuits cover investors who bought EMBC shares between Nov. 25, 2025 and May 4, 2026. Embecta reported Q2 fiscal 2026 revenue that fell more than 14%, far exceeding the company's prior guidance of flat to a 2% decline. The company also lowered its full-year 2026 outlook, citing weakness in US pen needle sales. Shares closed at $3.90 on May 5, down from about $9.28 the prior day.
The Schall Law Firm, DJS Law Group and Robbins LLP have all announced investigations or filed claims on behalf of shareholders. The lead plaintiff deadline is Aug. 17, 2026. A successful case could result in significant financial liability for the medical device company.
Embecta, which manufactures insulin delivery devices for people with diabetes, had reaffirmed its fiscal 2026 guidance during the class period, including confidence in its pen needle business, according to the complaints. The company spun off from Becton Dickinson in 2022.
The lawsuits allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Investors who suffered losses can contact the law firms to discuss their rights.
The litigation adds uncertainty to Embecta's recovery prospects as the company navigates declining demand in its core pen needle market. Investors will watch for the company's next quarterly filing and any settlement discussions ahead of the August lead plaintiff deadline.
This article is for informational purposes only and does not constitute investment advice.
